We know , south Asians have unique lipid profile where most of them have normal LDL levels. In spite of the fact, LDL is our primary target. Why ?
So, this question is being asked .Does low LDL lowers the CAD risk consistently , in south asians ?
The simple answer is : NO. To justify this, no long explanation is required. Just few ounces of common sense is suffice. CAD is multifactorial , polygenic disorder. Like the traditional coronary risk factors , we must have many Invisible coronary protective factors.How is that up to 40 % of ACS patients do not have single traditional cardiac risk factor ? Our current scientific thought process is so superficial, with that we are happy to enforce dogmatic guidelines targeting LDL in isolation.
Now let us enter the scientific arena.
Does low LDL lowers the CAD risk consistently , in south Asians ?
The answer is a definite yes. (But it requires a long explanation )
South Asian populations ( India, Pakistan, Bangladesh, Sri Lanka, and Nepal) experience a disproportionate and premature burden of atherosclerotic cardiovascular disease (ASCVD). The landmark global INTERHEART Study demonstrated that dyslipidaemia is the single strongest population level risk factor for acute myocardial infarction in South Asians.The extensive clinical and pathophysiological evidence justifying aggressive lipid-lowering and the mandatory use of statins in this population is structured below.
1. The Pathophysiological Paradox
Standard lipid panels can be deceptive in South Asian individuals. A patient may present with what appears to be “normal” or only mildly elevated low-density lipoprotein cholesterol (LDL-C), yet remain at an incredibly high risk for a major adverse cardiovascular event (MACE).
- Atherogenic Dyslipidaemia: Driven by systemic insulin resistance and visceral adiposity (the “thin-fat phenotype”), South Asians exhibit a triad of elevated triglycerides, profoundly low HDL-C, and high concentrations of Apolipoprotein B (ApoB).
- Small, Dense LDL Particles: Even when total LDL-C numbers mimic a low-risk profile, South Asians possess a vastly higher concentration of small, dense LDL particles. These particles are highly atherogenic because they easily penetrate the arterial wall, have a prolonged circulation time, and oxidize rapidly, accelerate plaque formation.
- Elevated Lipoprotein(a): South Asians have a genetically determined, elevated baseline of Lipoprotein(a) or Lp(a), a powerful independent risk factor for CAD. Because Lp(a) contains an LDL particle, lowering the background LDL-C as aggressively as possible is critical to tackle this non-modifiable risk.
2. Clinical Trial Evidence: Why “Lower is Better” even in South Asians
The principle of “lower is better” for LDL-C is universally proven by the Cholesterol Treatment Trialists’ (CTT) Collaboration, which established that every 1 mmol/L (38 mg/dL) reduction in LDL-C yields a consistent 22% reduction in major vascular events. However, for South Asians, this non-linear benefit applies even more due to their higher absolute baseline risk.
- Absence of a Lower Limit Threshold: Large-scale data from international trials (ADA ) confirm that the cardiovascular benefit of reducing LDL-C continues linearly to very low levels , without a threshold where the benefit stops.(Zero LDL?)
- The Power of Primary Prevention: Epidemiological registries consistently show that long-term statin therapy in South Asians reduces MACE, all-cause mortality, and coronary revascularization procedures across all risk groups including to those traditionally deemed as “low risk” by standard Western calculators.
3. Statin Mandates in International and Regional Guidelines
Because traditional risk calculators (like the US Pooled Cohort Equations or Europe’s SCORE) routinely underestimate ASCVD risk in South Asians, modern medical guidelines have adapted to mandate earlier and more aggressive statin implementation.
| Guideline | Clinical Status & Indication for statin | Target LDL |
|---|---|---|
| AHA / ACC | Classifies South Asian ethnicity as an explicit “Risk-Enhancing Factor.” Strongly favors initiating statins at younger ages (20–40) even for borderline risk. | Target aligned with primary/secondary prevention goals; typically <70 mg/dL for high risk. |
| Lipid Association of India (LAI) | States that South Asians develop ASCVD a decade earlier than Western populations. Focuses intensely on aggressive, early therapeutic intervention. | <50 mg/dL for Very High Risk; ≤30 mg/dL or lower for Extreme Risk categories. |
| National Lipid Association USA (NLA) | Endorses a tailored framework advocating for lower initiation thresholds and intensive statin management for South Asian diaspora | <50 mg/dL for those with very high cumulative risk scores. |
4. Maximizing Statin Safety and Pharmacokinetics
- Equivalent Lipid-Modifying Efficacy: Head to head clinical evaluations show that standard doses of atorvastatin and simvastatin reduce LDL-C and optimize HDL-C fractions in South Asian patients just as effectively as the western popualtion.
- Dosing: While east Asian populations possess clear genetic variations ( ABCG2 polymorphisms) that increase statin blood concentrations and require lower therapeutic doses, South Asians display different metabolic profiles. They safely achieve optimal target lipid goals using standard clinical guidelines.
Summary
For South Asians, lowering LDL cholesterol confers a direct protection against premature, aggressive coronary artery disease without doubt. Statins play a critical role in it.
